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ABSTRACT
After allogeneic hematopoietic stem cell transplantation (HSCT), early infections represent a major cause of
morbidity and mortality but little information has been previously reported on late infections. Late infection
incidence and risk factors were retrospectively determined in 196 long-term survivors after HLA matched
related HSCT. Patients transplanted for aplastic anemia, chronic myelogenous leukemia (CML), and acute
myelogenous leukemia (AML) were included. Median follow-up was 8 years. Thirty patients died beyond the
first year, causes of death were relapse (n 10) and infections (n 19, associated with graft-versus-host disease
[GVHD] in 16 patients). Late severe bacterial (LSB) and fungal infections occurred in 30 and 8 patients,
yielding to an 8-year cumulative incidence of 15 (95%CI: 10-20) and 4% (95%CI: 1-6), respectively. The
majority of viral infections were hepatitis C (HCV) and VZV (8-year cumulative incidence: 10 (95%CI: 5-14)
and 27% (95%CI: 20-34), respectively. Three risk factors for LSB have been identified in multiple Cox analysis:
CMV status (positive recipient and negative donor) (hazard ratio [HR]: 2.5, 95%CI: 1.1-5.9, P  .033),
irradiation-based conditioning regimen (HR: 3.1, 95%CI: 1.2-7.8, P  .016), and extensive chronic GVHD
(cGVHD; HR: 2.9, 95%CI: 1.3-6.9, P  .013). Extensive cGVHD was the only risk factor for non-HCV viral
infections in patients transplanted for AML or CML (HR: 2.7, 95%CI: 1.4-5.1, P .002). After HSCT, patients
remain at high risk of infections even late after transplantation, in particular, with the above risk factors, and
required a prolonged follow-up.
© 2007 American Society for Blood and Marrow Transplantation
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lNTRODUCTION
Although allogeneic hematopoietic stem cell trans-
lantation (HSCT) is a curative therapy for many
ematologic malignancies and aplastic anemia, its
idespread indication has been limited by graft-
ersus-host disease (GVHD). Indeed, GVHD in-
uces an immune defect directly and indirectly
hrough the use of immunosuppressive drugs, which
ay increase risk of late infections after transplan-
ation. Both GVHD and infections are subsequently
ajor causes of morbidity and mortality after
SCT [1]. Twenty percent to 70% of long-termurvivors who survive acute complications of the a
304ransplantation eventually suffer from chronic GVHD
cGVHD) and are prone to infections.
Concerning late infections, Aktinson et al. [2] re-
orted more than 20 years ago, infection rate in long-
erm survivors after HSCT. Among 98 patients alive
t least 6 months after HSCT, 18 experienced 1 or
everal late infections. Main risk factors were active
GVHD and HLA disparity [2]. Other studies showed
higher late infection rate in unrelated donor versus
elated donor recipients as well as in patients with
GVHD [3,4]. In a large multicentric retrospective
tudy published by Hoyle and Goldman in 1994 [5],
ife-threatening infections were diagnosed in 65 patients
mong 1007 HSCT recipients, and were fatal in the
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Late Infections after Transplantation 1305ajority of patients. Of note, the majority of the infec-
ions were diagnosed within the ﬁrst-year posttransplan-
ation. Concerning studies focused on speciﬁc viral in-
ections, Varicella Zoster virus (VZV) and hepatitis C
irus (HCV) appeared as major causes of morbidity in
ong-term and very long-term survivors [6-8].
Late severe infection incidence beyond the ﬁrst
ear after transplantation has been suggested as low
5%), in particular, in the setting of HLA matched
elated donors [2,3]. In this study, we thus aimed to
etermine incidence and risk factors for late infections
n patients with an expected low risk of infection.
ndeed, our study focused on patients who underwent
SCT from an HLA identical sibling donor and who
ere free of their primary disease at least 1 year after
SCT.
ATIENTS AND METHODS
atient Characteristics
Because our aim was the long-term assessment of
nfectious risk, we decided to focus this study on
atients alive 1 year after transplantation and consid-
able 1. Characteristics of the Patients at Transplantation and within
o. of patients
ean (range) age at transplantation, years
o. (%) age <15 years
o. (%) female
o. (%) female donor to male recipient
o. (%) positive CMV status
o. (%) positive CMV donor to negative recipient
o. (%) ABO incompatibility
Absence
Minor
Major
onditioning regimen, No. (%)
TBI or TAI
BuCy
VHD prophylaxis, No. (%)
CsA and MTX
CsA alone
MTX alone
edian (IQR) time to neutrophil recovery (500 threshold)
edian (IQR) time to platelet recovery (50 threshold)
o. (%) aGVHD
Grade I
Grade II
Grade III
Grade IV
o. (%) treated by steroids
o. (%) cGVHD within first year posttransplantation
Limited
Extensive
o. (%) CMV infection within first year posttransplantation
o. (%) Aspergillosis within first year posttransplantation
o. indicates number; vs., versus; AA, aplastic anemia; AML,
CMV, cytomegalovirus; TBI, total-body irradiation; TAI, thorac
acute graft-versus-host disease; cGVHD, chronic graft-versus-host disred at low risk of early transplant-related mortality
TRM), including only patients who received an un-
anipulated HSCT from an HLA-matched sibling
onor. This study focused on patients who received a
tandard myeloablative conditioning regimen (Table
). To have a homogenous sample of patients, only
atients with expected good disease-free survival (DFS)
ere included, excluding those patients with high risk of
elapse. Patients with acute myelogenous leukemia
AML) in ﬁrst or second complete remission (CR),
hronic myelogenous leukemia in ﬁrst chronic phase
CML), or acquired aplastic anemia (AA) were previ-
usly analyzed for long-term outcome showing close
verall DFS in the 3 groups, and these patients were
elected in the present study [9-11]. All patients who
ied or relapsed from their primary disease within the
rst posttransplantation year were excluded. Accord-
ng to all these criteria, 196 patients were identiﬁed
Table 1). All the charts of the 196 long-term survi-
ors were reviewed to search for infections, and all
igniﬁcant events occurring beyond the ﬁrst year were
ollected, including GVHD and its treatment, relapse,
nd infectious complications. All patients were fol-
otal AA AML CML
96 57 76 63
to 56) 21 (6 to 46) 26 (2 to 53) 35 (13 to 56)
4) 23 (40) 21 (28) 2 (3)
9) 24 (42) 37 (49) 35 (56)
2) 18 (32) 12 (16) 13 (21)
6) 40 (74) 36 (48) 31 (49)
1) 1 (2) 8 (11) 12 (19)
1) 45 (79) 54 (71) 36 (63)
8) 9 (16) 9 (12) 17 (30)
1) 3 (5) 13 (17) 4 (7)
9) 31 (54) 34 (47) 11 (18)
5) 0 (0) 36 (49) 51 (81)
4) 51 (90) 72 (95) 61 (98)
) 5 (9) 4 (5) 5 (2)
.5) 1 (2) 0 (0) 0 (0)
7 to 24) 22 (18 to 27) 18 (17 to 21) 19 (16 to 22)
0 to 47) 30 (24 to 44) 25 (18 to 50) 29 (21 to 47)
6) 19 (33) 31 (41) 21 (33)
3) 5 (9) 21 (27) 0 (0)
) 3 (5) 1 (1) 0 (0)
.5) 1 (2) 0 (0) 0 (0)
5) 23 (40) 53 (70) 52 (83)
0) 4 (7) 4 (5) 12 (19)
0) 20 (36) 12 (16) 26 (42)
2) 11 (19) 4 (5) 8 (13)
) 4 (7) 1 (1) 3 (5)
myeloblastic leukemia; CML, chronic myelogenous leukemia;
inal irradiation; BuCy, busulfan plus cyclophosphamide; aGVHD,1 Year
T
1
28 (2
46 (2
96 (4
43 (2
107 (5
21 (1
135 (7
35 (1
20 (1
76 (3
87 (4
184 (9
10 (5
1 (0
19 (1
29 (2
71 (3
26 (1
4 (2
1 (0
128 (6
20 (1
58 (3
23 (1
8 (4
acute
oabdomease; CsA, cyclosporin; IQR, interquartile range.
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M. Robin et al.1306owed at the Hôpital Saint Louis at least once a year if
o complications occurred. Almost all patients with a
linically signiﬁcant infection were hospitalized in
ôpital Saint Louis. If it was not the case, information
oncerning infection was collected in the charts on the
ext visit, or from written information coming from
orresponding physicians. Main patient, disease, and
ransplant characteristics have been previously re-
orted in detail [9-11]. These characteristics are sum-
arized in Table 1. Most patients received bone mar-
ow (N  191). Early antibiotic prophylaxis was given
ccording to standard procedure as already reported
9-11]. Amoxicillin was given at least 5 years after trans-
lantation, and was continued beyond 5 years if patients
ad cGVHD or received immunosuppressive treatment.
rimethoprim-sulfamethoxazole was withdrawn when
mmunosuppressive treatment was discontinued and
D4 count was0.4 109/L. Acyclovir was discontin-
ed when immunosuppressive treatment was stopped.
atients were vaccinated according to European recom-
endations [12]. Brieﬂy, all patients received Tetanus
oxoid, Diphteria toxoid, and Polio combined vaccine
ithin the ﬁrst year. Patients were vaccinated against
nﬂuenza A and B each year before the inﬂuenza
eason. Pneumococcal vaccination was given accord-
ng to physician’s discretion. Posttransplantation
vents occurring during the ﬁrst year after transplan-
ation are summarized in Table 1.
efinitions and Statistical Analysis
Infections that we took into account in this anal-
sis were:
. Severe bacterial infections requiring hospitaliza-
tion including pneumonia, sepsis syndrome, pyelo-
nephritis, meningitis, and ostomyelitis. Bronchitis,
sinusitis, and cystitis were excluded. Diagnoses of
infections were performed according to standard
criteria [13,14]. Of note, undocumented pneumo-
nia or sepsis syndromes that resolved after antibi-
otic treatment were considered as bacterial. In par-
ticular, sepsis without any documentation and
complicated from septic shock was considered
bacterial.
. Viral infections; all documented invasive viral
infections requiring hospitalization, namely in-
fections related to Herpes simplex virus, adeno-
virus, respiratory syncitial virus (RSV), human
papilloma virus (HPV) in an extensive form, Ep-
stein Barr Virus (EBV), cytomegalovirus (CMV).
In addition, we collected less severe, but more
common viral infections as VZV and viral hepa-
titis (B or C [HBV or HCV]). We did not include
benign, presumably viral, or upper airway infec-
tion in this study.
. Invasive fungal infections; involving the lung, cen-
tral nervous system, or septicemia. TGrade I to IV acute GVHD (aGVHD) was de-
ned according to published criteria [15,16]. cGVHD
as deﬁned as none, limited, and extensive [15,16]. All
urvival analyses were carried out with a 1-year land-
ark. All failure times were thus calculated from
-year posttransplant, and patients who died or re-
apsed during the ﬁrst year were excluded. Cumulative
ncidences of late infections were estimated in a com-
eting risk setting where death and relapse deﬁned the
ompeting events [17]. TRM incidence was estimated
n a competing risk setting where deaths related to
elapse or secondary cancer deﬁned competing events.
eaths related to infectious disease was considered
s an infection-related death even if patients had
GVHD at time of death. Potential prognostic factors
or late bacterial or viral infection and TRM were
ested using Cox proportional hazards models. The
ollowing covariates were analyzed by univariate anal-
sis: age and sex for patient and donor at HSCT;
ajor ABO incompatibility; conditioning regimen type
nd use of irradiation within the conditioning regimen;
evere aGVHD (grade II-IV); corticosteroid use for
VHD treatment; cGVHD within or after the ﬁrst
ear; CMV reactivation within the ﬁrst year. Addition-
lly, cGVHD occurring during follow-up and re-
eated bacterial infections as risk for bacterial infec-
ions and TRM were analyzed as time-dependant
ovariates in Cox models. For each outcome, factors
chieving a P-value.20 in the marginal analysis were
ncluded in a multivariable analysis. A backward step-
ise variable selection procedure was used to remove
actors with P-value .05 in the multiple model. Final
odels were adjusted for age and diagnosis if such
ariables were not retained by the procedure. The
roportional hazards assumption was tested using
rambsch and Therneau lack-of-ﬁt test [18]. Analyses
ere carried out using R 2.2.1 statistical package (The
Development Core Team, Vienna, Austria). P-val-
es .05 were regarded as indicating statistical signif-
cance. Results are presented as estimates and 95%
onﬁdence intervals (95%CI).
ESULTS
atient Outcome
aGVHD (grade II-IV) developed in 31 patients.
ithin the ﬁrst year posttransplantation, cGVHD de-
eloped in 78 patients, including 58 with an extensive
orm. After the ﬁrst year, 18 additional patients devel-
ped cGVHD, including 6 with an extensive form. In-
idence of late onset (1 year) cGVHD was 9% (Table
). Among the 196 patients, 15 patients relapsed from
heir primary malignancies and 1 patient with aplastic
nemia (AA) had late graft rejection (Table 2). One
undred sixty-six patients were alive at the last contact.
he median duration of follow-up was 7.9 years (range:
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Late Infections after Transplantation 1307.1-17.2 years). Nonrelapse causes of death were mostly
elated to either cGVHD (n 8) or infections (n 11).
nfections leading to death were: septic-like shock (n 
), pneumonia (n  2), acute ostomyelitis (n  1), or
nvasive fungal infection (n  2). Of note, among the
1 patients who died from infections, 8 patients had
lso cGVHD.
Eight-year overall and event-free survivals (OS,
FS) were respectively 83% (95%CI: 77-89) and 77%
95%CI: 70-84) for the overall group with better out-
ome in patients transplanted for AA with 8-year EFS of
2% (95%CI: 72-95). Eight-year TRM reached 11%
95%CI 6-15), with death from relapse or secondary
ancers as competing risks (Figure 1). Main risk factors
or TRM, adjusted on diagnosis, were late bacterial in-
ections (hazard ratio [HR]: 15.4, 95%CI: 4.70-50.70)
nd extensive cGVHD (HR: 9.24, 95%CI: 2.66-32.10).
hen we analyzed the impact of repeated bacterial in-
ections on the risk of TRM, it did not increase this risk
s compared to 1 single infection. The cumulative inci-
ence of life-threatening infections reached 22%
able 2. Characteristics of Patients Beyond the First Year after Transp
Total
umber of patients 196
umber of relapses 16
umber of deaths 30
Relapse 5
Secondary cancer 5
cGVHD 9
Infection 10
Other causes (murder) 1
-Year survival (95% CI) 82.8% (76.9-89.1)
-year EFS (95% CI) 76.8% (70.3-83.8)
GVHD beyond 1 year
Total No. 18
Limited, No. (%) 12
Extensive, No. (%) 6
8-Year cumulative incidence (95% CI) 9.3% (5.2-13.4)
evere bacterial infections
Patients with >1 infection 30
8-Year cumulative incidence (95% CI) 14.9% (9.6-20.2)
ungal infections
No patients with at least 1 infection 8
Aspergillosis 6
Candidiasis 2
8-Year cumulative incidence (95% CI) 3.6% (1.0-6.2)
iral infections
No patients with at least 1 infection 64
HCV 17
VZV 38
Others 16
8-Year cumulative incidence (95% CI)
Overall first infection 35.2% (27.8-42.5)
HCV 9.6% (4.8-14.3)
Non-HCV 27.1% (20.5-33.7)
arasitic infections
Toxoplasmosis 2
Pneumocystis 4
o., number; AA, aplastic anemia; AML, acute myeloblastic leukem
EFS, event-free survival; cGVHD, chronic graft-versus-host disease; H95%CI: 16-28); these life-threatening infections in-
luded all infections excluding VZV and viral hepatitis.
acterial Infection
Thirty patients had 40 late severe bacterial infec-
ions that occurred after the ﬁrst year posttransplan-
ation. Sepsis and pneumonia were the most common
nfections, accounting for 17 and 12 patients, respec-
ively. Details on infected organ and microorganism
re detailed in Table 3. Nine patients had 2 or more
acterial infections. The eight-year incidence of bac-
erial infections was 15% (95%: 9.6-20.2) for the over-
ll group, with the majority of bacterial infections
ccurring during the second year posttransplantation
ut without any plateau after this date (Figure 1).
umulative incidences of bacterial infections were not
ifferent according to primary disease (Table 2). In
nivariate analysis, risk factors associated with late
acterial infections are listed in Table 4. The inclusion
f late-onset (1 year) extensive cGVHD as a time-
n
AA AML CML
57 76 63
1 8 7
7 15 8
0 4 1
1 4 0
2 5 2
4 1 5
0 1 0
4.4% (74.2-96.1) 78.0% (67.6-90.0) 87.0% (79.0-95.8)
2.0% (71.7-94.6) 73.6% (63.0-85.9) 77.7% (67.7-89.2)
8 7 3
4 4 4
3 3 0
2.4% (3.7-21.1) 9.2% (2.7-15.8) 6.6% (0.0-12.9)
8 14 8
4.5% (4.0-25.0) 17.6% (8.8-26.4) 11.9% (3.4-20.4)
2 2 4
2 1 3
0 1 1
3.5% (0.0-8.3) 1.4 (0.0-4.0) 6.3 (0.3-12.4)
18 21 25
11 4 2
7 16 15
2 2 12
5.2% (21.0-49.5) 29.4% (18.4-40.4) 41.3% (27.9-54.8)
2.6% (9.7-35.5) 6.3% (0.1-12.5) 1.7% (0.0-5.0)
6.5% (6.5-26.5) 25.0 (14.6-35.4) 39.5 (26.2-52.8)
1 — 1
1 1 2
L, chronic myeloid leukemia; 95% CI, 95% conﬁdence interval;lantatio
8
8
1
1
3
2
1
ia; CM
CV, hepatitis C; VZV, varicella-zoster virus.
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M. Robin et al.1308ependent covariate did not change the overall results
n the risk of severe bacterial infections (Table 4).
hree signiﬁcant risk factors with close HRs, that is,
imilar impact on risk, were identiﬁed by multivariate
nalysis: extensive cGVHD within the ﬁrst year, irra-
iation-based conditioning regimen, and CMV status
CMV-negative donor for CMV-positive recipient)
Table 4 and Figure 2).
iral Infection
Most frequent infections were VZV, HCV, and
nvasive infection related to Herpes Simplex (Table
). Sixty-four patients had 71 viral infections lead-
ng to an 8-year cumulative incidence of viral infec-
ion of 35% (Table 2). Rare viral infections are
igure 1. TRM and cumulative incidence of severe bacterial infec-
ion. The solid curves represent 8-year cumulative incidence for
RM (A) and for infections (B).isted in Table 3. Non-HCV viral infections were Eore frequent in patients transplanted for CML,
hereas HCV occurred more frequently in patients
ransplanted for AA (Table 2 and Figure 3). In
nivariate analysis, risk factors for non-HCV viral
nfections were: CML diagnosis (HR: 2.67, 95%CI:
.23-5.77, P  .013), irradiation within the condi-
ioning regimen (HR: 0.65, 95%CI: 0.35-1.20,
 .17), conditioning regimen with busulfan and
yclophosphamide (HR: 1.73, 95%CI: .98-3.04,
 0059), and extensive cGVHD within 1 year
HR: 1.65, 95%CI: 0.93-2.91, P  .087). Addition-
lly, a signiﬁcant interaction between extensive
GVHD within 1 year and diagnosis was found (P 
018), with a clear effect in AML and CML patients,
ut not in AA patients. We thus performed separate
nalyses for patients with AA. In a Cox model ac-
ording to diagnosis and adjusted on recipient age,
xtensive cGVHD increased the risk of non-HCV
iral infection in patients with either AML or CML
HR: 2.70, 95%CI: 1.44-5.09, P  .002) but not in
able 3. Type of Late Infections
Bacterial Infections N
epsis
S. aureus 2
E. coli 2
Salmonella 1
Nondocumented 7
neumonia
Pneumococcus 3
H. influenza 1
Undocumented 11
Missing germ 2
eningitis
Pneumococcus 3
yelonephritis
E. coli 3
Nondocumented 1
astroenteritis
Clostridium 1
Salmonella 2
stomyelitis
Missing germ 1
Viral Infections N
epatitis
Hepatitis C virus 17
Hepatitis B virus 2
sophagitis
Herpes simplex virus 6
nteritis
Cytomegalovirus 2
Adenovirus 1
kin lesion
Varicella and zoster virus 38
Human papilloma virus 1
neumonia
Respiratory syncitial virus 2
BV reactivation 1
ancytopenia related to Parvovirus B19 1BV indicates Epstein-Barr virus.
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Late Infections after Transplantation 1309atients with AA (HR: 0.21, 95%CI: 0.03-1.67,
 .14).
ungal and Parasitical Infections
Eight fungal infections were diagnosed after the
rst year, including 6 invasive aspergillosis and 2 fun-
al septicemias with Candida species, given an 8-year
umulative fungal infection of 3.6% (95%CI: 1-6.2).
oxoplasmosis was diagnosed in 2 patients and pneu-
onia related to Pneumocystis jirovecii in 4 patients. No
tatistical analyses were performed because of the
able 4. Risk Factors for Late Severe Bacterial Infections
Univariate Analysis HR (95%CI) P
ransplantation after 1992 0.23 (0.087-0.61) .08
iagnosis
AA 1 Ref
AML 1.39 (0.58-3.31) .46
CML 0.82 (0.30-2.26) .70
ge >30 year-old 1.61 (0.77-3.36) .20
emale donor to male recipient 0.77 (0.29-2.02) .60
egative CMV donor to positive
recipient 1.97 (0.85-4.54) .11
MV infection within first year 1.16 (0.40-3.33) .78
ajor ABO incompatibility 1.05 (0.32-3.46) .94
BI or TAI 3.85 (1.69-9.77) .001
uCy 0.48 (0.21-1.09) .080
GVHD grade >II 1.85 (0.79-4.33) .16
reatment by steroids 4.90 (1.48-16.2) .009
xtensive cGVHD within first year 2.99 (1.44-6.20) .003
Multivariate Analysis HR (95%CI) P
rradiation in conditioning regimen 3.11 (1.24-7.83) .016
egative CMV donor to positive
recipient 2.53 (1.08-5.94) .033
xtensive cGVHD within 1 year 2.94 (1.26-6.88) .013
Analysis of Impact of GVHD Onset
on late bacterial infection risk HR (95%CI) P
rognostic factor
GVHD within 1 year
None 1 Ref
Limited 0.95 (0.21-4.26) .95
Extensive 2.97 (1.39-6.35) .005
xtensive cGVHD within 1 year 2.99 (1.44-6.20) .003
GVHD (including follow-up)
None 1 Ref
Limited 1.16 (0.31-4.31) .82
Extensive 3.74 (1.68-8.33) .001
xtensive cGVHD (including
follow-up) 3.61 (1.74-7.50) .0006
A indicates aplastic anemia; AML, acute myeloblastic leukemia;
CML, chronic myelogenous leukemia; 95% CI, 95% conﬁdence
interval; cGVHD, chronic graft-versus-host disease; aGVHD,
acute graft-versus-host disease; HCV, hepatitis C; VZV, vari-
cella-zoster virus; TBI, total-body irradiation; TAI, thoraco-
abdominal irradiation; BuCy, busulfan plus cyclophosphamide;
HR, hazard ratio; BuCy, busulfan plus cyclophosphamide;
CMV, cytomegalovirus.mall number of patients.igure 2. Eight-year cumulative incidence of bacterial infection.
ight-year cumulative incidence of bacterial infection according to
xtensive cGVHD within 1 year (upper left); irradiation in condi-
ioning regimen (upper right); CMV status (positive recipient and
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M. Robin et al.1310ISCUSSION
The increased risk of late infections after trans-
lantation has rarely been measured, whereas persis-
ence of biologic immune defect has already been
eported in patients with GVHD [19]. In this retro-
pective, single-center study, we showed that the in-
idence of late infections remains high in related
SCT recipients beyond 1 year after transplantation.
ndeed, the 8-year cumulative incidence of life-threat-
ning infections reached 22%. Furthermore, bacterial
nfections were the major risk factor, associated with
igure 3. Cumulative incidence of viral infection. In A, an 8-year
umulative incidence of nonhepatitis C viral infection displayed in
atients with chronic myelogenous leukemia (-·-·), acute myeloblas-
ic leukemia (---), and aplastic anemia (– –). In B, an 8-year cumu-
ative incidence of hepatitis C infection is displayed in chronic
yelogenous leukemia (-·-·), acute myeloblastic leukemia (---), and
plastic anemia (– –).GVHD, for TRM in multivariate analysis.Late bacterial infections occurred in 30 patients,
eading to a 15% cumulative incidence. In compari-
on, Ochs et al. [3] reported that 94 of 151 related
onor transplant recipients developed an infection be-
ween 50 days and 2 years after transplantation. Of
ote, the bacterial infections represented half of in-
ectious diseases and 10% of them occurred beyond
he ﬁrst year in the Mineapolis group experience [3].
In our study we identiﬁed in a multivariate anal-
sis, 3 major risk factors for bacterial infections.
. cGVHD was a major bacterial infection risk fac-
tor, as expected [3,20]. Different mechanisms
inducing immune failure in patients with
cGVHD have been reported. Functional asplenia
detected by Howell-Jolly bodies in peripheral
blood cells has been described after HSCT, in
particular in patients with extensive GVHD [21].
cGVHD has been also reported to impair both T
cells and B cells reconstitution [20]. Thymus
dysfunction decreasing naïve T cell generation
also has been recently reported to be related to
cGVHD [20,22]. Furthermore, GVHD immu-
nosuppressive treatment clearly increases the risk
of opportunistic infections [20].
. Irradiation in conditioning regimen was another
risk factor for late bacterial infections. Malignant
and nonmalignant late effects of irradiation have
been progressively described with the increased
number of long-term survivors. Higher risk of
deaths not related to relapse has been reported in
patients treated by irradiation-based conditioning
regimens, in particular after single-dose of total
body irradiation (TBI) [23]. In our study, both
single and fractionated doses were used, before and
after 1994, respectively. Before and after this date,
irradiation remained a risk factor for bacterial in-
fection, which means that both single and fraction-
ated irradiation doses increased the risk of bacterial
infections (data not shown). The increased risk of
bacterial infections after an irradiation-based con-
ditioning regimen may be linked to functional
asplenia following splenic irradiation [24]. This
functional asplenia has been also described in au-
tologous transplantation recipients who are at
higher risk of pneumococcal infections only if they
have been subjected to total body irradiation [4].
Furthermore, an increased risk of late infection
after TBI has been reported after autologous trans-
plantation [25].
. In our study, a seronegative CMV donor increased
the risk of bacterial infections in a seropositive
recipient. Recipient CMV status has been reported
to inﬂuence outcome [26], whereas the impact of
donor CMV status remains controversial, in par-
ticular, in the setting of HLA matched related
transplantation [27-29]. Preemptive CMV-treat-
ment strategies might have decreased the risk of
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Late Infections after Transplantation 1311death related to CMV and prolonged survival of
profoundly immunocompromised patients allow-
ing other infections to occur later. Similarly, others
have reported an increased risk of death from bac-
terial, viral, or fungal infection in seropositive re-
cipient receiving a graft from a seronegative CMV
donor [27,30]. Furthermore, CMV itself or its
treatment has been suggested to be immunosup-
pressive [27,31,32].
The fact that extensive cGVHD was not the only
isk factor for bacterial infections in our study de-
erves special comments. Indeed, cGVHD has been
eported to overwhelm all other factors in multivariate
nalysis in other studies [33-35]. Our study aimed to
elect patients surviving at least 1 year after transplan-
ation. Only patients with the less severe form of
xtensive cGVHD had survived beyond this ﬁrst year,
hich might have induced a bias in analysis. Never-
heless, it shows that in these conditions, other risk
actors can be identiﬁed.
Among viral reactivation, VZV was the most fre-
uent, occurring in 38 patients. Of note, non-HCV
iral infections were less frequent in patients with AA.
he 8-year cumulative incidence of non-HCV viral
nfection rose 27%. VZV-related complications such
s bacterial superinfection or disseminated VZV as
ell as mortality attributable to VZV, were not ob-
erved in our study, suggesting that VZV reactivation
s less severe beyond the ﬁrst year. However, it is
oteworthy that patients remained at high risk of late
ZV reactivation, although VZV has been reported to
ypically occur within the ﬁrst year after transplanta-
ion [8,36]. cGVHD was the only risk factor identiﬁed
or non-HCV viral infection. Several immunologic
bnormalities have been previously described, but a
ZV-speciﬁc immune defect related to cGVHD is
ontroversial [37,38]. A recent study by Boeck et al. [8]
howed that the major risk factor for VZV after trans-
lantation was immunosuppressive therapy rather
han GVHD itself, but both are, of course, interre-
ated.
Hepatitis C was the other frequent viral infection,
ccurring in 17 patients. Of note, patients with AA
ere more susceptible to HCV infection because of
ultiple pretransplant blood transfusions related to
plasia. HCV infections occurred in patients trans-
lanted before the early 1990s, when efﬁcient blood
creening procedures were not available yet [6,7].
CV in our study reﬂects a posttransplantation diag-
osis when efﬁcient diagnostic tools were available,
ithout prejudging if the patient was infected by
lood products before or after transplantation. As pre-
iously reported by our group as well as others, HCV-
elated morbidity is not negligible, increasing the risk
f very late cirrhosis several decades after the onset of
he infection [6,7], and should be identiﬁed in long-
erm survivors.In conclusion, HSCT recipients, even from HLA
atched related donors, remain at high risk for late
nfections. Extensive cGVHD as well as CMV status and
rradiation in a conditioning regimen, are major risk
actors for bacterial infection. A life-long surveillance is
hus mandatory in these otherwise cured patients.
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